News & Updates
Filter by Specialty:
More syphilis cases picked up with universal vs targeted ED screening
Relying on targeted screening models for syphilis in emergency departments (EDs) leaves a substantial number of active cases undetected, new research shows.
More syphilis cases picked up with universal vs targeted ED screening
24 Mar 2025
Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis
When treating late latent syphilis during pregnancy, extending the interval between benzathine penicillin G (BPG) doses to 9 days may put newborns at risk of congenital infection relative to 6–8-day intervals, according to new research.
Prenatal BPG delivery: 9-day treatment interval linked to higher risk of congenital syphilis
23 Mar 2025
Ensitrelvir safe, effective in preventing COVID-19 in households
Treatment with ensitrelvir among household contacts (HHC) of index patients (IP) with COVID-19 within 72 h after the onset of IP symptoms demonstrates efficacy and an acceptable safety profile as postexposure prophylaxis (PEP) in SCORPIO-PEP, a phase III placebo-controlled trial.
Ensitrelvir safe, effective in preventing COVID-19 in households
21 Mar 2025
First HIV cure trial affirms tolerability of investigational combo in women with HIV
A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.
First HIV cure trial affirms tolerability of investigational combo in women with HIV
21 Mar 2025
Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV
Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.
